Melbourn, U.K., Feb. 25 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) is pleased to announce the appointment of Peter Chambre as the Company's new Chief Executive Officer (CEO) with effect from early April. He will join the CAT Board at that time.
Peter Chambre was Chief Operating Officer at Celera Genomics Group until November 2001. Previously he held the post of CEO at Bespak PLC, a global supplier of drug delivery technology and delivery systems in the field of inhaled therapies. He has also held positions at Bain & Company, Unilever PLC and others.
Peter Garland, CAT's Chairman, commented ``We are delighted that Peter has agreed to join CAT at this time when the Company is positioning itself for transition to a profitable biopharmaceutical business. We believe that with his considerable experience as a CEO and of other senior management roles, both in the UK and the US, Peter has the right mix of skills and experience to lead CAT through the next phase of its development.''
``David Chiswell will leave CAT in early April. On behalf of the whole of the Board of CAT, I would like to place on record our appreciation to him for his contribution to CAT since its formation and for his unstinting hard work in making the Company the success it is today. His legacy is one of which he can be truly proud.''
Peter Chambre, CAT's new CEO, commented, ``I am excited by the opportunity at CAT and am very much looking forward to joining the Company. CAT is already a highly regarded leader in developing human antibody therapeutics and I believe that it is in a strong position to make the evolution that is already underway to a profitable biopharmaceutical company. Together with its talented management and employees, I believe that we can build a great future for CAT. David is leaving behind a strong company and I fully recognise the role that he has played in its success to date.''
Dr. David Chiswell, CAT's outgoing CEO, said ``I am pleased that we have identified a successor of obvious calibre in a relatively short period of time. Peter's record to date is impressive and I am confident he can lead the Company successfully through the challenges ahead. I wish him every success.''
* Notes to Editors:
* Peter Chambre - Biography and Details
* Education: Reading University, BSc (Hons) Food Science
* Career details: 1976-1978 Cadbury Schweppes PLC, Marketing Research;
1978-1983 Unilever PLC, Senior Brand Manager; 1983-1988 Bain & Company
* (global strategy consultancy), Vice President; 1988-1992 Cope Allman Packaging PLC, Chief Operating Officer; 1992-1993 Novar PLC (previously Caradon PLC), Divisional Chief Executive; 1994-2000 Bespak plc, Chief Executive Officer (led the development of the company into a leading supplier of drug delivery technology and delivery systems to the inhaled therapies and biopharmaceutical markets with operations in Europe and US); 2000-2001 Celera Genomics Group, Chief Operating (key achievements include the redefinition of company strategy toward transformation into biopharmaceutical company and the acquisition and integration of Axys Pharmaceuticals, Inc).
* Nationality: British
* Marital Status: Married with five children
* Age: 46 ... |
